Track topics on Twitter Track topics that are important to you
Danish pharmaceutical company Novo Nordisk A/S on Wednesday reported flat second-quarter net profit, but lifted its growth targets for the year on expectations of robust sales of its type-2 diabetes drug Victoza and long-acting insulin Tresiba. Sales in the quarter got a boost from sales of new diabetes and obesity drugs, but growth in North America was pegged back by adjustments to rebates and competition from generic drugs.
Original Article: Novo Nordisk profit flat; upbeat on sales outlookNEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...